trial

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

NCTId NCT03319953
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 23 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2019-09-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
23 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2017-12-21
Primary completion
2019-09-11
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
TAK-041Second Generation Antipsychotics (SGA)

Sponsors

Neurocrine BiosciencesLead Sponsor
TakedaCollaborator

Investigators

1
Medical Director Clinical ScienceStudy Director

Sites

1 total
London, United Kingdom

Linked catalysts

1
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of — primary completion2019-09-11

Facts & assertions

4 sourced
Enrollment
23
Phase
PHASE2
Primary Completion Date
2019-09-11
Status
COMPLETED
relationships
The graph out of here
drug
TAK-041
drug
Second Generation Antipsychotics (SGA)
drug
lead_sponsor
Neurocrine Biosciences
company
collaborator
Takeda
company
indication
Stable Schizophrenia
indication
investigator
Medical Director Clinical Science
person